Stockscreener 앱 받기
44.69
0.90%
0.40
시장 영업 전:
44.21
-0.48
-1.07%
전일 마감가:
$44.29
열려 있는:
$44.29
하루 거래량:
459.67K
Relative Volume:
0.59
시가총액:
$3.45B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-16.31
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
+0.45%
1개월 성능:
+14.33%
6개월 성능:
+46.72%
1년 성능:
+5.55%
1일 변동 폭
$43.25
$44.75
1주일 범위
$42.35
$44.81
52주 변동 폭
$26.74
$45.01
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
44.69 | 3.42B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
How Xenon Pharmaceuticals Inc. stock performs in rate cut cyclesJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares - Investing.com
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? - Yahoo Finance
Xenon Pharmaceuticals to Host Webinar on Epilepsy Data and Commercialization Plans - TipRanks
Xenon (Nasdaq: XENE) sets AES 2025 webinar on azetukalner epilepsy data, commercialization - Stock Titan
JPMorgan Chase & Co. Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Loomis Sayles & Co. L P Sells 15,846 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
American Century Companies Inc. Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Expands 2025 Equity Incentive Plan - TipRanks
(XENE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Ameritas Investment Partners Inc. Acquires Shares of 7,758 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention - sahmcapital.com
Xenon Reports Second Quarter 2025 Financial Results & Business Update - ADVFN
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week HighTime to Buy? - MarketBeat
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD - Investing.com
Xenon Pharmaceuticals to Present New Epilepsy Research at AES 2025 - TipRanks
Xenon Pharmaceuticals to Present New Data on Azetukalner and Epilepsy at American Epilepsy Society Annual Meeting 2025 - Quiver Quantitative
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 - Caledonian Record
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? - sharewise.com
FY2025 Earnings Estimate for XENE Issued By Chardan Capital - Defense World
Is Xenon Pharmaceuticals Inc. stock a dividend growth opportunityQuarterly Profit Report & Daily Profit Focused Screening - newser.com
Envestnet Asset Management Inc. Decreases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - Defense World
How Xenon Pharmaceuticals Inc. stock performs during Fed tightening cyclesQuarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Why Xenon Pharmaceuticals Inc. stock is recommended by analystsPortfolio Profit Report & Long-Term Growth Plans - newser.com
Why Xenon Pharmaceuticals Inc. stock could outperform in 2025Trend Reversal & AI Enhanced Execution Alerts - newser.com
Short interest data insights for Xenon Pharmaceuticals Inc.Weekly Profit Summary & Real-Time Buy Signal Alerts - newser.com
Can Xenon Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling & AI Forecasted Stock Moves - newser.com
Technical signs of recovery in Xenon Pharmaceuticals Inc.Weekly Volume Report & Target Return Focused Picks - newser.com
Bank of New York Mellon Corp Raises Stock Position in Xenon Pharmaceuticals Inc. $XENE - Defense World
Xenon Pharmaceuticals at Jefferies London: Advancing Epilepsy and Pain Treatments - Investing.com Canada
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $60.00 Price Target at JPMorgan Chase & Co. - Defense World
XENE: JP Morgan Raises Price Target to $60, Maintains Overweight Rating | XENE Stock News - GuruFocus
Using Ichimoku Cloud for Xenon Pharmaceuticals Inc. technicalsSwing Trade & Risk Managed Investment Strategies - newser.com
How strong is Xenon Pharmaceuticals Inc. stock revenue growthWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):